Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.57 |
| ▸ | LGALS3 | P17931 | 6/20 | 0.57 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.57 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.48 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.48 |
| ▸ | AMY2A | P04746 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30655225 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL4809768 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL30651917 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL29844043 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL15233925 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL3244652 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL30122667 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL3247667 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL31453733 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL30870430 | 1.00 | CD69 (0.57) | CD69LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | CD69 2506/4885LGALS3 236/4885LGALS8 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.